Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative...
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative...

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative...

Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg.

DSIJ Intelligence-1 Article rating: 5.0
The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas...
Medical Equipment & Supplies Expands Global Reach in Medical Devices; Secures USFDA Registration
Medical Equipment & Supplies Expands Global Reach in Medical Devices; Secures USFDA Registration

Medical Equipment & Supplies Expands Global Reach in Medical Devices; Secures USFDA Registration

Company's products are available both online, through its proprietary store and major e-commerce platforms, and offline, with a presence in over 22,000 retail touchpoints across 460+ towns in India.

DSIJ Intelligence-1 Article rating: 5.0
The company's wholly-owned subsidiary, Nureca Technologies Pvt Ltd, specializes in manufacturing medical devices...
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR